Real-World, Long-Term Data Collection to Gain Clinical Insights Into Faricimab for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

What this Trial Is About

Researchers are studying the use of faricimab in patients with neovascular age-related macular degeneration nAMD or diabetic macular edema DME affecting at least one eye. This observational study aims to evaluate the effectiveness, safety, treatment patterns, and health economics of faricimab in real-world clinical practice over a two-year follow-up period. The study includes patients both new to anti-VEGF treatment and those who have been previously treated with anti-VEGF therapies. Participants will receive faricimab as guided by local clinical practice and labeling. The study divides participants into two sub-cohorts based on their prior eye treatment history those naive to anti-VEGF treatment and those previously treated. The study is designed to observe treatment regimens, dosing, and clinical outcomes in routine care settings without experimental interventions. During the study, participants will be monitored for changes in visual acuity and central subfield thickness at multiple time points up to 24 months. Researchers will collect data on injection frequency, treatment intervals, and any switch in treatment. Safety will be assessed by tracking ocular and non-ocular adverse events. The study emphasizes the collection of real-world clinical and economic data, following each patient for up to two years.

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)